This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Prevention of hepatitis B virus (HBV) infection is essential to HIV-infected patients. Vaccination with hepatitis B vaccine has proven to yield protective levels of antibodies in greater than 90% of vaccinated immunocompetent adults. Unfortunately, HIV-infected patients respond poorly to vaccination, at rates ranging from 17.5% to 56% with standard HBV vaccination strategies. The reason for the poor immune response is intriguing; both vaccine factors and the host immune system may play a role. In other immunocompromised patient populations, including transplant patients and dialysis patients, response to hepatitis B vaccine is poor, but successful strategies have improved responses, by increasing the number of doses, increasing the dose size, using adjuvants to vaccine, and administering booster vaccinations when antibody titers wane. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is an immunomodulatory cytokine and is an excellent candidate to be a vaccine adjuvant.A5220 is a two-arm, randomized, phase II, open-label pilot study to evaluate the efficacy and safety of hepatitis B vaccine with and without GM-CSF as an adjuvant in HIV-infected, HBV-uninfected subjects na ve to HBV vaccination with CD4+ cell counts ?200 cells/mm3. The study is 60 weeks in duration. 48 subjects (24 per arm) will participate. The study population will be HIV-infected subjects na ve to HBV vaccination, ?18 years of age, with CD4+ cell counts ?200 cells/mm3, and seronegative for previous HBV and hepatitis C virus (HCV) infection (hepatitis B core total antibody [HBcAb total], qualitative hepatitis B surface antibody [HBsAb], hepatitis B surface antigen [HBsAg], and HCV antibody tests performed within 30 days prior to entry must be nonreactive [negative]). Subjects will be stratified by their screening plasma HIV-1 RNA levels: 10 mIU/mL) at 16 weeks. 2) To evaluate the predictive value of HBsAb levels at 4 weeks and 24 weeks after completion of the vaccination series on the durability of response (defined as HBsAb 10 mIU/mL at 48 weeks after completion of the vaccination series). 3) To evaluate the effect of these HBV vaccination strategies on HIV viral load.
Showing the most recent 10 out of 470 publications
